Cancer genomics biotech to make debut on Nasdaq
Genetron Holdings is set to start trading this week on the Nasdaq, joining a number of Chinese biotechs listing there, even as the U.S. looks to approve more stringent requirements for Chinese companies on U.S. exchanges.
The Beijing-based company is seeking to raise over $200 million after it upped its share offering from 13 million to 16 million shares late last week.
Founded in 2014, Genetron develops genomic profiling solutions for cancer research, diagnosis, and monitoring. According to its F-1 filing, the company can provide diagnostic services for eight of the top 10 cancers in China, analyzing whole exomes of up to 21,000 genes. It has also developed a technology platform and proprietary assays to allow early detection and intervention of liver cancer.
The Beijing-based company is seeking to raise over $200 million after it upped its share offering from 13 million to 16 million shares late last week.
Founded in 2014, Genetron develops genomic profiling solutions for cancer research, diagnosis, and monitoring. According to its F-1 filing, the company can provide diagnostic services for eight of the top 10 cancers in China, analyzing whole exomes of up to 21,000 genes. It has also developed a technology platform and proprietary assays to allow early detection and intervention of liver cancer.
.png)
No hay comentarios:
Publicar un comentario